Challenges faced by the global polio eradication initiative

@article{Wassilak2010ChallengesFB,
  title={Challenges faced by the global polio eradication initiative},
  author={Steven G. F. Wassilak and Walter A. Orenstein},
  journal={Expert Review of Vaccines},
  year={2010},
  volume={9},
  pages={447 - 449}
}
After the World Health Assembly resolved in 1988 to eradicate wild poliovirus (WPV) transmission globally by 2000, dramatic progress in reducing polio cases and increasing the number of countries that interrupted indigenous WPV transmission was made by 2000 [1]. In 2010, 10 years past the target date and with US$7 billion of external funds expended since the beginning of the effort, some individuals question the feasibility of reaching the goal [2,3]. This editorial will provide an overview of… 
Disease Eradication in the 21st Century: Implications for Global Health
TLDR
The most pertinent lessons were in assessing operational feasibility, sustaining and applying research, conducting effective advocacy at the subnational level, operating in insecure areas, and anticipating and addressing vulnerabilities in areas with especially weak health systems.
Vaccine-preventable diseases in Europe: where do we stand?
TLDR
More flexible vaccine delivery platforms are needed targeting the less-privileged people, especially in the context of the current economic crisis, and healthcare personnel and healthcare systems should be prepared to address these challenges in the following years.
Profile of polio-compatible cases in Nigeria, 2006–2016
TLDR
The epidemiological profile and magnitude of polio-compatible cases in Nigeria during the reporting period, as well as immunization and surveillance response activities conducted to close immunity and surveillance gaps, are highlighted.
Environmental Surveillance for Polioviruses in Haïti (2017–2019): The Dynamic Process for the Establishment and Monitoring of Sampling Sites
TLDR
Environmental surveillance for polioviruses in Haïti was established in Port au Prince and Gonaïves in 2016, and during 2017–2019, initial ES sites were re-evaluated, and ES was expanded into Cap Haïtien and Saint Marc.
Eradicating polio: persisting challenges beyond endemic countries
TLDR
This paper aims to provide a forward-looking, evidence-based, and scalable approach to the development and use of vaccine-preventable and non- vaccine-reinforcing components of the next generation of polio vaccines.
A quantitative survey of the literature on poliovirus infection and immunity.
Polio inactivated vaccine costs into routine childhood immunization in Brazil
TLDR
The concomitant replacement of the DTPw/Hib and HepB vaccines with the pentavalent vaccine enabled the introduction of the inactivated polio without increasing the number of injections or number of visits needed to complete the vaccination.
Evaluation of the Acute Flaccid Paralysis Surveillance System in Polio-Free Jordan, 2012-2016: Retrospective Secondary Analysis
TLDR
The AFP surveillance system in Jordan is performing well; however, additional efforts are needed to strengthen the subnational sensitivity and the cold chain from sample collection to laboratory testing has to be maintained to ensure the reliability of stool specimens required for isolation of the nonpolio enterovirus.
Polio inactivated vaccine costs into routine childhood immunization in Brazil Custos da vacina inativada de pólio na imunização infantil de rotina no
TLDR
The concomitant replacement of the DTPw/Hib and HepB vaccines with the pentavalent vaccine enabled the introduction of the inactivated polio without increasing the number of injections or number of visits needed to complete the vaccination.
Evaluation of the Acute Flaccid Paralysis Surveillance System in Polio-Free Jordan, 2012-2016: Retrospective Secondary Analysis (Preprint)
TLDR
The AFP surveillance system in Jordan is performing well; however, additional efforts are needed to strengthen the subnational sensitivity and the cold chain from sample collection to laboratory testing has to be maintained to ensure the reliability of stool specimens required for isolation of the nonpolio enterovirus.
...
...

References

SHOWING 1-10 OF 20 REFERENCES
Progress toward interruption of wild poliovirus transmission--worldwide, January 2007-April 2008.
  • Medicine
    MMWR. Morbidity and mortality weekly report
  • 2008
TLDR
Programmatic strategies implemented in 2007 included expanded use of type 1 monovalent oral poliovirus vaccine (OPV) (mOPV1) to eliminate type 1 WPV transmission before type 3 WPV (WPV3) and targeted use of types 3 and 4 OPV in selected areas.
Vaccine-derived polioviruses and the endgame strategy for global polio eradication.
TLDR
Two other adverse events have been identified more recently: long-term excretion of highly evolved vaccine-derived polioviruses (VDPVs) in persons with primary immunodeficiencies, and polio outbreaks associated with circulating VDPVs in areas with low rates of OPV coverage.
Polio today: are we on the verge of global eradication?
TLDR
In 1953 at the height of polio epidemics in the United States, Salk and colleagues described preliminary findings that led to an inactivated poliovirus vaccine and the induction of neutralizing serum antibodies in human participants appeared to be entirely attributable to the noninfectious experimental vaccines.
Monovalent type 1 oral poliovirus vaccine in newborns.
TLDR
When given at birth, monovalent type 1 oral poliovirus vaccine is superior to trivalent oral Poliomyelitis vaccine in inducing humoral antibodies against type 1Poliovirus, overcoming high preexisting levels of maternally derived antibodies, and increasing the resistance to excretion of type 1 poliov virus after administration of a challenge dose.
Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
  • V. CáceresR. Sutter
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
TLDR
Single-dose monovalent Sabin vaccines are highly immunogenic and safe and should be considered for stockpiles of vaccine to provide an effective response to potential outbreaks of poliomyelitis in the post-eradication period.
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.
TLDR
Although advances in molecular biology may ultimately lead to the development of more-immunogenic vaccine candidates, approaches such as increasing the number of doses of TOPV, mass vaccination campaigns, and combined use of oral and inactivated vaccines should also be considered.
The risks, costs, and benefits of possible future global policies for managing polioviruses.
TLDR
It is found that after successful eradication of wild polioviruses, OPV cessation would save both costs and lives when compared with continued use of OPV without supplemental immunization activities.
...
...